Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “sell” rating reissued by Zacks Investment Research in a note issued to investors on Saturday, February 10th.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Several other brokerages have also recently issued reports on VYGR. Stifel Nicolaus reissued a “buy” rating and set a $31.00 target price (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Wedbush reissued a “positive” rating and set a $31.00 target price (down previously from $36.00) on shares of Voyager Therapeutics in a report on Tuesday, October 31st. Chardan Capital reaffirmed a “hold” rating and issued a $17.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, October 31st. Cowen reaffirmed a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, October 31st. Finally, Robert W. Baird started coverage on shares of Voyager Therapeutics in a report on Monday, October 30th. They issued an “outperform” rating and a $31.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $26.90.
Voyager Therapeutics (NASDAQ VYGR) traded up $0.19 during trading hours on Friday, hitting $19.36. 169,959 shares of the stock traded hands, compared to its average volume of 289,731. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99. The firm has a market capitalization of $526.91 and a P/E ratio of -6.82.
In related news, insider Bernard Ravina sold 2,451 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $18.24, for a total transaction of $44,706.24. Following the transaction, the insider now directly owns 4,902 shares in the company, valued at $89,412.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 11,571 shares of company stock worth $179,067 over the last 90 days. 8.00% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in Voyager Therapeutics by 73.9% in the 4th quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock valued at $20,099,000 after purchasing an additional 514,345 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Voyager Therapeutics by 290.5% in the 4th quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock valued at $10,870,000 after purchasing an additional 487,147 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Voyager Therapeutics by 19.2% in the 4th quarter. Wells Fargo & Company MN now owns 449,525 shares of the company’s stock valued at $7,462,000 after purchasing an additional 72,335 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Voyager Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after purchasing an additional 13,194 shares during the last quarter. Finally, AXA acquired a new position in Voyager Therapeutics in the 4th quarter valued at about $5,591,000. Institutional investors own 36.42% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Voyager Therapeutics (NASDAQ:VYGR) Given “Sell” Rating at Zacks Investment Research” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/17/voyager-therapeutics-vygr-stock-rating-reaffirmed-by-zacks-investment-research.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.